TY - JOUR
KW - COMT inhibitor
KW - Entacapone
KW - Parkinson's disease
KW - health care resource usage (HCRU)
KW - opicapone
AU - G. Harrison-Jones
AU - X. Marston
AU - F. Morgante
AU - Ray Chaudhuri
AU - G. Castilla-Fernández
AU - V. Foggia
AD - Bial Pharma UK Ltd, Windsor, UK.
OPEN Health, Evidence & Access, Marlow, UK.
Neurosciences Research Centre, Molecular and Clinical Sciences Research Institute, St. George's University of London, London, UK.
Department of Clinical and Experimental Medicine, University of Messina, Italy.
Parkinson Foundation International Centre of Excellence, Kings College Hospital and Kings College London, London, UK.
BIAL R&D Investments, S.A., Portugal.
AN - 37489574
BT - Eur J Neurol
DO - 10.1111/ene.15990
DP - NLM
ET - 2023/07/25
LA - eng
N1 - 1468-1331
Harrison-Jones, Glynn
Marston, Xiaocong Li
Morgante, Francesca
Orcid: 0000-0002-9834-3639
Ray Chaudhuri, K
Castilla-Fernández, Guillermo
Foggia, Valentina Di
Orcid: 0009-0002-7242-5502
Journal Article
England
Eur J Neurol. 2023 Jul 25. doi: 10.1111/ene.15990.
PY - 2023
SN - 1351-5101
T2 - Eur J Neurol
TI - Opicapone versus entacapone: Head-to-head retrospective data-based comparison of healthcare resource utilization in people with Parkinson's new to COMT inhibitor treatment
ER -